{
  "findings": [
    {
      "id": "Q01",
      "metric": "Fraction of tumor proteins represented in immunopeptidome",
      "value": "62.3%",
      "comparator_or_baseline": "37.3%",
      "interpretation": "Intratumoral mRNA vaccination is associated with broader antigen display in the tumor immunopeptidome.",
      "evidence_line_refs": ["L28"]
    },
    {
      "id": "Q02",
      "metric": "Fraction of proteins represented in MHC-I peptidome",
      "value": "40.6%",
      "comparator_or_baseline": "20.6%",
      "interpretation": "The MHC-I-presented peptide landscape expands substantially after intratumoral mRNA vaccination.",
      "evidence_line_refs": ["L29"]
    },
    {
      "id": "Q03",
      "metric": "Retrospective human survival comparison p-value",
      "value": "p=0.01",
      "comparator_or_baseline": "N/A",
      "interpretation": "In the retrospective cohort, vaccinated patients had statistically improved survival under ICI treatment.",
      "evidence_line_refs": ["L30"]
    },
    {
      "id": "Q04",
      "metric": "Type I interferon response score (normalized units)",
      "value": "3.1",
      "comparator_or_baseline": "1.0",
      "interpretation": "Tumors show a marked induction of a type I interferon response after mRNA vaccination.",
      "evidence_line_refs": ["L31"]
    },
    {
      "id": "Q05",
      "metric": "PD-L1 expression fold-change in tumor tissue",
      "value": "2.4x",
      "comparator_or_baseline": "1.0x",
      "interpretation": "PD-L1 pathway activity increases, supporting a mechanistic rationale for checkpoint blockade combination.",
      "evidence_line_refs": ["L32"]
    },
    {
      "id": "Q06",
      "metric": "Intratumoral CD8+ T-cell density fold-change",
      "value": "1.8x",
      "comparator_or_baseline": "1.0x",
      "interpretation": "Combination therapy increases CD8+ T-cell infiltration relative to baseline.",
      "evidence_line_refs": ["L33"]
    }
  ],
  "controls_or_null_results": [
    {
      "statement": "Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.",
      "evidence_line_ref": "L36"
    },
    {
      "statement": "ICI-only treatment had limited activity in low-immunogenic baseline settings.",
      "evidence_line_ref": "L37"
    },
    {
      "statement": "Lipid particle controls lacking mRNA did not reproduce the sensitization effect.",
      "evidence_line_ref": "L38"
    },
    {
      "statement": "Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.",
      "evidence_line_ref": "L39"
    }
  ]
}
